F5 and Pulmonary hemorrhage: A review on acquired FV inhibitors reported that bleeding symptoms, including hematuria, gastrointestinal bleeding, hematoma, intracranial hemorrhage, and pulmonary hemorrhage, were observed in patients, while, notably, 23% of patients were asymptomatic [8].